Method and reagent for determining biologically active heparin in plasma
AssigneeBoehringer Mannheim GmbH
InventorsKnut Bartl, Helmut Lill, Joachim Ziegenhorn
Life of this patent
Estimating the term…
Abstract
A method for determining biologically active heparin comprising adding, in the absence of exogenous antithrombin III, a proteolytic enzyme selected from the group consisting of thrombin and factor Xa and a chromogen substrate for the enzyme to a heparin sample, measuring the dye released from the chromogen substrate and thus determining the amount of heparin present.
Claims7
Method for the determination of the biological activity of heparin in plasma which method comprises
- adding to the heparin sample a proteolytic enzyme selected from thrombin or factor Xa, and a chromogen substrate of said proteolytic enzyme, without addition of exogenous antithrombin III, and measuring the dye released from the chromogen substrate as a measure of the heparin activity initially present.
Reagent for the determination of heparin in plasma consisting essentially of
- 0.01 to 0.3 moles/l of buffer, pH 6 to 9
- 0.01 to 0.25 moles/l of alkali chloride,
- 200 to 1100 NIH/l of thrombin
- 0.05 to 10 mmoles/l of chromogen substrate for thrombin,
- 0 to 0.01 g/l of aprotinin,
- 0 to 10 g/l of polyethylene glycol.
- 0 to 0.03 moles/l EDTA
Reagent for the determination of heparin in plasma consisting essentially of
- 0.01 to 0.3 moles/l of buffer, pH 6 to 9
- 0.01 to 0.25 moles/l of alkali chloride,
- 200 to 1100 NIH/l of factor Xa,
- 0.05 to 10 mmoles/l of chromogen substrate for factor Xa,
- 0 to 0.01 g/l of aprotinin,
- 0 to 10 g/l of polyethylene glycol.
- 0 to 0.03 moles/l EDTA
Dependencies are inferred from the claim text.